A Phase 1b study to evaluate the safety, pharmacokinetics, and anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously in combination with different drugs in patients with advanced solid tumours

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504376-21-00

Enrollment

Registered

2023-07-24

Start date

2023-08-28

Completion date

Unknown

Last updated

2025-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic ductal adenocarcinoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026